Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6636462 | 0.90 | SMN1; SMN2 (0.55) | LMNAKMT2AMEN1ABCC1SMN1; SMN2 | |
| SCHEMBL6640226 | 0.88 | KMT2A (0.45) | NPSR1LMNAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6793704 | 0.85 | SMN1; SMN2 (0.57) | LMNAKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6643804 | 0.83 | KMT2A (0.47) | NPSR1LMNAKMT2AMEN1ABCC1 | |
| SCHEMBL6790153 | 0.83 | ALDH1A1 (0.47) | LMNAKMT2AMEN1ABCC1SMN1; SMN2 | |
| SCHEMBL6638121 | 0.82 | KMT2A (0.49) | NPSR1KMT2AABCC1ALDH1A1GHSR | |
| SCHEMBL6641230 | 0.82 | ABCC1 (0.43) | NPSR1LMNAKMT2AMEN1ABCC1 | |
| SCHEMBL6638646 | 0.81 | RORC (0.45) | LMNAKMT2AMEN1ABCC1SMN1; SMN2 | |
| SCHEMBL6802163 | 0.81 | KMT2A (0.43) | LMNAKMT2AMEN1ABCC1SMN1; SMN2 | |
| SCHEMBL6793097 | 0.81 | ALDH1A1 (0.45) | LMNAKMT2AMEN1ABCC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100576-A1 | Methods and compounds for inhibiting mrp1 | ABCC1, ABCB11, ABCB1 | NPSR1 1536/4885LMNA 2226/4885KMT2A 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.